X0508 4/A 2025-04-08-05:00 2025-02-25-05:00 false 0001582554 Matinas BioPharma Holdings, Inc. MTNB 0002056785 Pembroke & Partners LLC 1345 AVENUE OF THE AMERICAS 27TH FLOOR NEW YORK NY 10105 false false true false false Series C Convertible Preferred Stock 0.586 2025-04-08-05:00 4 P false 492 1000.00 A 2025-04-04-05:00 Common Stock 839591 984 D Warrants 0.6446 2025-04-08-05:00 4 P false 1679182 A 2025-04-08-05:00 2030-04-08-05:00 Common Stock 1679182 3358364 D Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants. Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Pembroke voting power based on the Preferred Stock of up to 23% of the outstanding Common Stock. Pembroke's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants. N/A /s/ Robert J. Eide 2025-04-10-05:00